206 related articles for article (PubMed ID: 20442367)
1. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
Balakrishnan K; Burger JA; Quiroga MP; Henneberg M; Ayres ML; Wierda WG; Gandhi V
Blood; 2010 Aug; 116(7):1083-91. PubMed ID: 20442367
[TBL] [Abstract][Full Text] [Related]
2. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
3. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
6. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
7. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
8. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
Chen R; Guo L; Chen Y; Jiang Y; Wierda WG; Plunkett W
Blood; 2011 Jan; 117(1):156-64. PubMed ID: 20971952
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
10. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP.
Davenne T; Klintman J; Sharma S; Rigby RE; Blest HTW; Cursi C; Bridgeman A; Dadonaite B; De Keersmaecker K; Hillmen P; Chabes A; Schuh A; Rehwinkel J
Cell Rep; 2020 May; 31(6):107640. PubMed ID: 32402273
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.
Balakrishnan K; Burger JA; Fu M; Doifode T; Wierda WG; Gandhi V
Neoplasia; 2014 Dec; 16(12):1036-46. PubMed ID: 25499217
[TBL] [Abstract][Full Text] [Related]
12. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part I.
Kamath VP; Xue J; Juarez-Brambila JJ; Morris CB; Ganorkar R; Morris PE
Bioorg Med Chem Lett; 2009 May; 19(10):2624-6. PubMed ID: 19386498
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.
Kamath VP; Xue J; Juarez-Brambila JJ
Bioorg Med Chem Lett; 2009 May; 19(10):2627-9. PubMed ID: 19386496
[TBL] [Abstract][Full Text] [Related]
15. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
16. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.
Kurtova AV; Balakrishnan K; Chen R; Ding W; Schnabl S; Quiroga MP; Sivina M; Wierda WG; Estrov Z; Keating MJ; Shehata M; Jäger U; Gandhi V; Kay NE; Plunkett W; Burger JA
Blood; 2009 Nov; 114(20):4441-50. PubMed ID: 19762485
[TBL] [Abstract][Full Text] [Related]
17. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
19. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.
Balakrishnan K; Burger JA; Wierda WG; Gandhi V
Blood; 2009 Jan; 113(1):149-53. PubMed ID: 18836097
[TBL] [Abstract][Full Text] [Related]
20. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG.
Ghosh AK; Kay NE; Secreto CR; Shanafelt TD
Clin Cancer Res; 2009 Feb; 15(4):1250-8. PubMed ID: 19228728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
